Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|April 1, 1989
Surrogate endpoints in clinical trials: cardiovascular diseasesJ Wittes, E Lakatos, J Probstfield
JAMA|July 3, 1991
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trialsS Yusuf, J Wittes, J Probstfield, et al.
Lancet (London, England)|January 11, 2002
Blood-pressure reduction and cardiovascular risk in HOPE studyP Sleight, S Yusuf, J Pogue, et al.
Controlled Clinical Trials|May 5, 1999
Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly ProgramJ Wittes, E Lakatos, D Black, et al.
American Journal of Hypertension|December 1, 1995
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP)J B Kostis, K G Berge, B R Davis, et al.
Controlled Clinical Trials|February 1, 1996
Community volunteers as recruitment staff in a clinical trial: the systolic hypertension in the elderly program (SHEP) experienceS Hertert, G Bailey, V Cottinghan, et al.
Statistics in Medicine|June 15, 1992
Analysis strategies for serial multivariate ultrasonographic data that are incompleteM A Espeland, R P Byington, D Hire, et al.
Circulation|July 21, 1999
Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research GroupR P Byington, G W Evans, M A Espeland, et al.
Circulation|October 3, 2001
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramiprilJ Mathew, P Sleight, E Lonn, et al.
Controlled Clinical Trials|December 12, 2001
Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)S Pressel, B R Davis, G T Louis, et al.
Pageof 2